Expert panel review on Alzheimer’s drug aducanumab becomes a one-day trial by fire as critics turn their guns on Biogen — and the FDA
Two days after an enthusiastic FDA insider review of Biogen’s aducanumab provided a $15 billion pop for the big biotech’s market cap, a panel of outside experts provided some fresh fireworks on the debate, with a big majority turning thumbs down on the controversial pitch that there are data to prove the drug is effective — as well as the agency’s perplexing endorsement.
Most of the experts slapped down 3 questions regarding whether there was any evidence to back the efficacy of the drug — with a lone vote in favor on one of the questions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
